Mpox

Mpox is an exotic infectious disease caused by the Mpox virus. The disease was first identified in laboratory monkeys, thus earning its name, but in its natural state, it seems to infect rodents more than primates. A fever, headache, muscle pains, swollen lymph nodes, and fatigue are the first symptoms in humans. After this, a rash forms with blisters and crusts. Symptoms typically appear 7 to 14 days after exposure. In most cases, symptoms last 2 to 4 weeks. Children, pregnant women, and people with suppressed immune systems are at greater risk of severe cases.

Overview

Feature Articles

Latest Mpox News and Research

WHO expands Emergency Use Listing for mpox diagnostics

WHO expands Emergency Use Listing for mpox diagnostics

New initiative activated to strengthen response to mpox public health crisis

New initiative activated to strengthen response to mpox public health crisis

African production of mpox vaccines could secure the continent’s health

African production of mpox vaccines could secure the continent’s health

Vaccination of young children could dramatically reduce mpox deaths in DRC

Vaccination of young children could dramatically reduce mpox deaths in DRC

New single-chain mRNA vaccines offer enhanced immunity and protection against mpox

New single-chain mRNA vaccines offer enhanced immunity and protection against mpox

New consortium launched to combat Mpox outbreak in Africa

New consortium launched to combat Mpox outbreak in Africa

A review of clinical features, diagnosis, and management of Mpox

A review of clinical features, diagnosis, and management of Mpox

Novel app enables surveillance of global travel-related illness

Novel app enables surveillance of global travel-related illness

FAU researchers highlight new vaccination barriers

FAU researchers highlight new vaccination barriers

WHO lists first mpox in vitro diagnostic test under Emergency Use Listing

WHO lists first mpox in vitro diagnostic test under Emergency Use Listing

New Health Impact Investment Platform launches to strengthen primary care

New Health Impact Investment Platform launches to strengthen primary care

Single dose of MVA-BN vaccine offers 58% protection against mpox

Single dose of MVA-BN vaccine offers 58% protection against mpox

NIH funds new research to combat emerging viruses

NIH funds new research to combat emerging viruses

New mechanism aims to ensure equitable distribution of mpox vaccines and treatments

New mechanism aims to ensure equitable distribution of mpox vaccines and treatments

WHO adds MVA-BN vaccine to prequalification list as first vaccine against mpox

WHO adds MVA-BN vaccine to prequalification list as first vaccine against mpox

Researchers find no evidence of monkeypox infection in pets, despite presence of viral DNA

Researchers find no evidence of monkeypox infection in pets, despite presence of viral DNA

Avian influenza detected in Texas wastewater samples

Avian influenza detected in Texas wastewater samples

Single dose of MVA-BN vaccine shows 58% effectiveness against mpox

Single dose of MVA-BN vaccine shows 58% effectiveness against mpox

Mpox inactivated in 60 seconds with Σ-MM™ & patient friendly collection swab

Mpox inactivated in 60 seconds with Σ-MM™ & patient friendly collection swab

Study finds Lassa fever infection rates to be far greater than previously believed

Study finds Lassa fever infection rates to be far greater than previously believed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.